HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will Oklahoma Dextromethorphan Age Restriction Bill Lead The Way?

This article was originally published in The Tan Sheet

Executive Summary

Increasing momentum in states for age restrictions on sales of dextromethorphan-containing cough/cold products could drive retail industry support for a federal bill mandating a uniform, nationwide age restriction

You may also be interested in...

Biden dex bill expected

A bill from Sen. Joe Biden, D-Del., that would place an age restriction of 18 on OTC sales of dextromethorphan is likely to be introduced before the August recess. The bill will not include language establishing pre-emption over potential state bills with greater restrictions, according to staffers, but will include funding for abuse prevention education efforts. Biden has worked with input from manufacturers and retailers (1"The Tan Sheet" March 12, 2007, p. 3). The bill will also address abuse of bulk DXM...

FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class

FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff

First DXM Age Law Passes While Voluntary Restrictions Increase

A New York county adopts an ordinance limiting sales of dextromethorphan products to consumers 19 years old and up, while trade groups are looking to a uniform national solution that will curb abuse, maintain consumer access and limit retailer burdens

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts